Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 4/20 | 0.52 |
| ▸ | CTSA | P10619 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14661878 | 0.92 | PANK3 (0.52) | PIN1CTSAHTR2CTLR7PANK3 | |
| SCHEMBL14662575 | 0.92 | PIN1 (0.48) | PIN1CTSAFFAR2HPGDSTDP1 | |
| SCHEMBL14661956 | 0.89 | TLR7 (0.48) | PIN1CTSAHTR2CTLR7PANK3 | |
| SCHEMBL14662374 | 0.89 | PIN1 (0.53) | PIN1CTSATYRHPGDSAPLNR | |
| SCHEMBL14662249 | 0.88 | PIN1 (0.52) | PIN1CTSATYRHPGDSTDP1 | |
| SCHEMBL14661926 | 0.88 | PIN1 (0.67) | PIN1TLR7HPGDSTDP1MAPT | |
| SCHEMBL14716874 | 0.85 | PIN1 (0.56) | PIN1TLR7TYRRAB9AHPGDS | |
| SCHEMBL14662578 | 0.84 | PIN1 (0.46) | PIN1CTSAHTR2CTLR7FFAR2 | |
| SCHEMBL14717457 | 0.83 | PIN1 (0.55) | PIN1CTSATLR7NPC1RAB9A | |
| SCHEMBL14662703 | 0.81 | PIN1 (0.52) | PIN1CTSATLR7RAB9AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736891-B1 | SUBSTITUTED 3-(THIAZOLE-4-CARBONYL)- OR 3-(THIAZOLE-2-CARBONYL)- AMINOPROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-04-20 | — | — | EP | claimed |
| US-9174952-B2 | Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | claimed |
| US-20130053402-A1 | SUBSTITUTED 3-THIAZOLOAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-02-28 | — | — | US | claimed |
| EP-2736891-B1 | SUBSTITUTED 3-(THIAZOLE-4-CARBONYL)- OR 3-(THIAZOLE-2-CARBONYL)- AMINOPROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-04-20 | — | — | EP | disclosed |
| US-9174952-B2 | Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| WO-2014053533-A1 | USE OF SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AS PHARMACEUTICALS FOR PREVENTION/TREATMENT OF ATRIAL FIBRILLATION | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-20130053402-A1 | SUBSTITUTED 3-THIAZOLOAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053402-A1 | SUBSTITUTED 3-THIAZOLOAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSK | PIN1 2555/4885CTSA 11/4885HTR2C 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.